Multicentric, Randomized, Double-Blind Study Versus Placebo, With Two Parallel Groups Treated to Evaluate the Efficacy and the Tolerance of Riluzole in Children and Young Adults (6 to 20 Years of Age) With SMA. (Type II and Type III).
Phase of Trial: Phase II/III
Latest Information Update: 14 Feb 2013
At a glance
- Drugs Riluzole (Primary)
- Indications Spinal muscular atrophy
- Focus Therapeutic Use
- Acronyms ASIRI
- 21 Sep 2011 Planned end date changed from 1 Jun 2010 to 1 Dec 2011 as reported by ClinicalTrials.gov.
- 07 Nov 2008 New trial record.